Investment Rating - The report assigns a "Buy" rating for the company, marking its initial coverage [2][3]. Core Insights - The company possesses a globally scarce humanized only heavy chain antibody platform, establishing a core competitive barrier [2]. - The platform's value enhances business development (BD) potential, with recognized R&D capabilities and stable collaborations with multinational corporations (MNCs) like AstraZeneca [2][3]. - The company is expected to see significant profit growth due to its strong pipeline in the autoimmune sector and multiple ongoing projects [3]. Summary by Sections 1. R&D Platform Technology Value - The company focuses on innovative drug development and commercialization in oncology and immune diseases, leveraging its unique HCAb technology platform [12]. - Established in 2016, the company has developed proprietary platforms for generating human monoclonal antibodies [13]. 2. HCAb Harbour Mice: Scarce Humanized Only Heavy Chain Antibody Platform - The HCAb platform is the only patented humanized only heavy chain antibody development platform globally, capable of producing various antibody forms [31][38]. - The platform's unique advantages include high solubility, stability, and the ability to generate diverse antibody libraries [34]. 3. Strong BD Capabilities with MNC Collaborations - The company has established a robust BD strategy, focusing on early-stage pipeline collaborations with major pharmaceutical companies [62]. - Significant partnerships include a global strategic collaboration with AstraZeneca, enhancing the company's market position and financial stability [63][70]. 4. Competitive Product Lines in Autoimmune Sector - The company is set to launch its product, Bartoli monoclonal antibody, which targets myasthenia gravis, in collaboration with CSPC [3]. - Another promising pipeline candidate, HBM9378, is in Phase II clinical trials for asthma and COPD, indicating strong market potential [3]. 5. Earnings Forecast and Valuation - The company is projected to achieve revenues of $154.08 million and net profits of $81.75 million by 2025, with a target price of HKD 18.80 [3].